The marketing analysis of antibacterial drugs of the azitrimicine group for use in pediatrics

Authors

  • I. O. Fedyak SHHE «Ivano-Frankivsk National Medical University», Ukraine
  • I. P. Bilyk SHHE «Ivano-Frankivsk National Medical University», Ukraine

DOI:

https://doi.org/10.24959/sphhcj.18.106

Keywords:

azithromycin, pertussis, marketing analysis, pharmaceutical market, availability indices

Abstract

Aim. To assess the state of the Ukrainian pharmaceutical market for azithromycin drugs used to treat infection diseases in children, including pertussis.
Materials and methods. The marketing analysis of azithromycin drugs was conducted by the method of monthly monitoring of the range, average wholesale prices, social and economic availability coefficients (cost liquidity (Cliq), adequacy of the population solvency (Ca.s), availability (A) according to the resource “Program complex “Apteka” (Pharmacy)” (http://pharmbase.com.ua/) for 2015 and 2017.
Results. It was found that by December 2017 products of foreign manufacture were dominated (66 %) among azithromycin drugs: the share of Russian manufacturers was 23 %, Israeli – 22 %, Slovenian – 18 %. Among the domestic producers of azithromycin the Ukrainian-Spanish company Sperko Ukraine and KMP (by 20 %) represented the largest number of these products. By dosage forms, 98 % of drugs were for oral use: tablets (45 %), powders for suspensions (31 %), and capsules (22 %). The price analysis of azithromycin drugs in the form of capsules (250 mg, No. 6) and powders for suspensions revealed a wide range of wholesale prices. Among the packs of capsule drugs the cheapest domestic generics were: Azithromycin-KP, Red Star – 24.63 ± 0.22 UAH and Azithromycin-Astrapharm – 24.94 ± 0.22 UAH, and among the powders for suspensions there was also domestic Azimed® 200 mg/5 ml, KMP (18.53 ± 0.7 UAH per 1 DDD).
Conclusions. The assessment of the social and economic availability of azithromycin drugs by monitoring liquidity ratios, adequacy of solvency, availability makes it possible to consider them financially affordable for the average family in Ukraine with a pertussis sick child. At the same time, the analysis of dosage forms has revealed a significant lack of pediatric dosages of J01FA10 group.

References

Duda, O., Veha, A. (2016). Mystetstvo likuvannia, 3–4, 42–49.

MOZ Ukrainy. (2004). Nakaz vid 09.07.2004 No. 354 “Pro zatverdzhennia Protokoliv diahnostyky ta likuvannia infektsiinykh khvorob u ditei”. Available at: http://www.moz.gov.ua/ua/portal/ dn_20040709_354.html

Ispolzovanie azitromitsina v pediatrii: prakticheskie rekomendatsii. (2014). Mezhdunarodnyi zhurnal pediatrii, akusherstva i ginekologii, 2, 60–62. Available at: http://ijpog.org/downloads/14/60–62.pdf

Yulish, E. (2013). Zdorove rebenka, 7, 109–114.

Adebayo, A., McFarlane, N. (2014). Model–based bioequivalence assessment of a commercial Azithromycin capsule against Pfizer Zithromax tablet marketed in Jamaica. Journal of Applied pharmaceutical science, 4 (10), 062 – 068. doi: 10.7324/JAPS.2014.40112.

Kotvitska, A., Korobova, Y. (2014). Upravlinnia, ekonomika ta zabezpechenniayakosti v farmatsii, 3 (35), 50–56.

Kotvitska, A., Korobova, Y. (2016). Sotsialna farmatsiia v okhoroni zdorovia, 4, 24–31. doi : 10.24959/ sphhcj.16.57

Zimenkovskyi, A., Ryvak, T. (2009). Klinichna farmatsiia, farmakoterapiia ta medychna standartyzatsiia, 1–2, 81–85.

Hadyak, I., Hrom, O., Komar, A. (2011). Farmatsevtychnyi zhurnal, 1, 19–24.

Yakovlieva, L., Shapoval, O., Hladkova, L. (2013). Dytiachy ilikar, 5, 31–34.

Yakovlieva, L., Matiashova, N. (2013). Upravlinnia, ekonomika ta zabezpechennia yakosti v farmatsii, 2 (28), 94–99.

Matiashova, N., Lytovchenko, A. (2015). Proceedings of formation of a national medical policy in the context of the implementation of health insurance: education, theory and practice: materialy III vseukrainskoi naukovo–osvit. Internet–konferentsii (12 bereznia 2015). (pp. 248–249). Kharkiv: NUPh.

Kramarev, S. (2014). Mezhdunarodnyi zhurnal pediatrii, akusherstva i ginekologii, 1, 52–57.

Etobaeva, I., Botoeva, E., Rodnaeva, O. (2015). Sovremennye problemy nauki i obrazovaniia, 2 (1). Available at: http://www.science–education.ru/ru/article/view?id=18508.

Nemchenko, A., Kosiachenko, K., Kubarieva, I. et al. (2011). Metodychni rekomendatsii z provedennia derzhavnoi ekspertyzy ta reiestratsii na osnovni likarski zasoby. Kharkiv: NFaU, 22.

Fediak, I., Ivaniulyk, I. (2016). Farmatsevtychnyi chasopys, 4, 24–32.

Derzhavnyi reestr lіkars’kykh zasobіv. On–line versіia. Available at: http://www.moz.gov.ua/ua/portal/ mtph_register_medicines/.

Downloads

Published

2018-03-14

Issue

Vol. 4 No. 1 (2018)

Section

Social marketing and pharmacoeconomic research

License

Copyright (c) 2018 National University of Pharmacy

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors who publish with this journal agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
  3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).